TY - JOUR
T1 - Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial
T2 - study protocol for a randomized controlled trial
AU - Endo, Akira
AU - Yamakawa, Kazuma
AU - Tagami, Takashi
AU - Umemura, Yutaka
AU - Takahashi, Kyosuke
AU - Nagasawa, Hiroki
AU - Araki, Yuichi
AU - Kojima, Mitsuaki
AU - Sera, Toshiki
AU - Yagi, Masayuki
AU - Yamamoto, Ryo
AU - Takahashi, Jiro
AU - Nakane, Masaki
AU - Takeda, Chikashi
AU - Narita, Chihiro
AU - Kazuma, Satoshi
AU - Okura, Hiroko
AU - Takahashi, Hiroyuki
AU - Wada, Takeshi
AU - Tahara, Shu
AU - Matsuoka, Ayaka
AU - Masaki, Todani
AU - Shiraishi, Atsushi
AU - Shimoyama, Keiichiro
AU - Yokokawa, Yuta
AU - Nakamura, Rintaro
AU - Sageshima, Hisako
AU - Yanagida, Yuichiro
AU - Takahashi, Kunihiko
AU - Otomo, Yasuhiro
N1 - Funding Information:
This work was supported by the Japan Society for the Promotion of Science KAKENHI (grant number: JP21H03197).
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: Hemodynamic stabilization is a core component in the resuscitation of septic shock. However, the optimal target blood pressure remains debatable. Previous randomized controlled trials suggested that uniformly adopting a target mean arterial pressure (MAP) higher than 65 mmHg for all adult septic shock patients would not be beneficial; however, it has also been proposed that higher target MAP may be beneficial for elderly patients, especially those with arteriosclerosis. Methods: A multicenter, pragmatic single-blind randomized controlled trial will be conducted to compare target MAP of 80–85 mmHg (high-target) and 65–70 mmHg (control) in the resuscitation of septic shock patients admitted to 28 hospitals in Japan. Patients with septic shock aged ≥65 years are randomly assigned to the high-target or control groups. The target MAP shall be maintained for 72 h after randomization or until vasopressors are no longer needed to improve patients’ condition. To minimize the adverse effects related to catecholamines, if norepinephrine dose of ≥ 0.1 μg/kg/min is needed to maintain the target MAP, vasopressin will be initiated. Other therapeutic approaches, including fluid administration, hydrocortisone use, and antibiotic choice, will be determined by the physician in charge based on the latest clinical guidelines. The primary outcome is all-cause mortality at 90 days after randomization. Discussion: The result of this trial will provide great insight on the resuscitation strategy for septic shock in the era of global aged society. Also, it will provide the better understanding on the importance of individualized treatment strategy in hemodynamic management in critically ill patients. Trial registration: UMIN Clinical Trials Registry; UMIN000041775. Registered 13 September 2020.
AB - Background: Hemodynamic stabilization is a core component in the resuscitation of septic shock. However, the optimal target blood pressure remains debatable. Previous randomized controlled trials suggested that uniformly adopting a target mean arterial pressure (MAP) higher than 65 mmHg for all adult septic shock patients would not be beneficial; however, it has also been proposed that higher target MAP may be beneficial for elderly patients, especially those with arteriosclerosis. Methods: A multicenter, pragmatic single-blind randomized controlled trial will be conducted to compare target MAP of 80–85 mmHg (high-target) and 65–70 mmHg (control) in the resuscitation of septic shock patients admitted to 28 hospitals in Japan. Patients with septic shock aged ≥65 years are randomly assigned to the high-target or control groups. The target MAP shall be maintained for 72 h after randomization or until vasopressors are no longer needed to improve patients’ condition. To minimize the adverse effects related to catecholamines, if norepinephrine dose of ≥ 0.1 μg/kg/min is needed to maintain the target MAP, vasopressin will be initiated. Other therapeutic approaches, including fluid administration, hydrocortisone use, and antibiotic choice, will be determined by the physician in charge based on the latest clinical guidelines. The primary outcome is all-cause mortality at 90 days after randomization. Discussion: The result of this trial will provide great insight on the resuscitation strategy for septic shock in the era of global aged society. Also, it will provide the better understanding on the importance of individualized treatment strategy in hemodynamic management in critically ill patients. Trial registration: UMIN Clinical Trials Registry; UMIN000041775. Registered 13 September 2020.
KW - Arterial pressure
KW - Geriatrics
KW - Hypotension
KW - Sepsis
KW - Vasoconstrictor agents
UR - http://www.scopus.com/inward/record.url?scp=85138457803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138457803&partnerID=8YFLogxK
U2 - 10.1186/s13063-022-06732-9
DO - 10.1186/s13063-022-06732-9
M3 - Article
C2 - 36153530
AN - SCOPUS:85138457803
SN - 1745-6215
VL - 23
JO - Trials
JF - Trials
IS - 1
M1 - 799
ER -